Dergiler / Infectious diseases and clinical microbiology (Online) / 2020 / Cilt: 2 - Sayı: 3

Adaptation of Acinetobacter baumannii tocolistin exposure: Laboratory Mimicking of aClinical Case

Sayfa
133–137
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A. baumannii can develop a stable colistin-resistant phenotype with elevatedMICs and upregulated pmrCAB operon after three weeks of colistin exposure.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Colistin resistance is an emerging threat.
📊
Temel Bulgular & Veri:To mimic theeffects of colistin in laboratory conditions, three colistin susceptible A.baumannii isolatedfrom the patient were exposed daily to colistin for up to 40 days.
💡
Sonuç & Katkı:A. baumannii can develop a stable colistin-resistant phenotype with elevatedMICs and upregulated pmrCAB operon after three weeks of colistin exposure.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Colistin resistance is an emerging threat. Here, we presented the development of colistinresistance in A. baumannii after colistin use on a disease course of a patient. To mimic theeffects of colistin in laboratory conditions, three colistin susceptible A.baumannii isolatedfrom the patient were exposed daily to colistin for up to 40 days. The colistin MICs andpmrABC expressions of each generation were studied. After 25 days of colistin treatment,colistin-resistant A. baumannii was isolated from the intra-abdominal fluid of the patient.During the in vitro study, the expressions of pmrCAB reached the highest level at thegeneration that corresponds to the duration of colistin therapy on the isolation day of theisolate.In conclusion, the duration of colistin exposure is critical for the development of colistinresistance. A. baumannii can develop a stable colistin-resistant phenotype with elevatedMICs and upregulated pmrCAB operon after three weeks of colistin exposure.

🔖

Bu Makaleye Atıf Yap

ERGÖNÜL, Ö., KESKE, Ş., CAN, F., ORALKAN, E. (2022). Adaptation of Acinetobacter baumannii tocolistin exposure: Laboratory Mimicking of aClinical Case. Infectious diseases and clinical microbiology (Online), Cilt: 2 - Sayı: 3, 133–137. https://ajindex.com/articles/539100

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. 1 Giamarellou H. Epidemiology of infections caused by polymyxin-resistant pathogens. Int J Antimicrob Agents 2016; 48: 614-21. 2 Macesic N, Green D, Wang Z, Sullivan SB, Shim K, Park S, et al. Detection of mcr-1-carrying Escherichia coli causing bloodstream infection in a New York City hospital: avian origins, human concerns? Open Forum Infect Dis 2017; 4: ofx115. 3 Hua X, Liu L, Fang Y, Shi Q, Li X, Chen Q, et al. Colistin resistance in Acinetobacter baumannii MDR-ZJ06 revealed by a multiomics approach. Front Cell Infect Microbiol 2017; 7: 45. 4 Clinical and Laboratory Standards Institute. Performance standards for Antimicrobial Susceptibility Testing: 20th Informational Supplement. Wayne, PA: CLSI. 2010. 5 Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-7. 6 Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55: 3370-9. 7 Ergonul O, Aydin M, Azap A, Basaran S, Tekin S, Kaya Ş, et al. Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. J Hosp Infect 2016; 94: 381-5. 8 Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008; 36: 807-11. 9 Charretier Y, Diene SM, Baud D, Chatellier S, Santiago-Allexant E, van Belkum A, et al. Colistin heteroresistance and involvement of the PmrAB regulatory system in Acinetobacter baumannii. Antimicrob Agents Chemother 2018; 62: e00788-18. 10 Macesic N, Nelson B, Uhlemann AC. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: de novo or drug exposure? Clin Infect Dis 2017; 65: 702-3. 11 Thi Khanh Nhu N, Riordan DW, Do Hoang Nhu T, Thanh DP, Thwaites G, Huong Lan NP, et al. The induction and identification of novel colistin resistance mutations in Acinetobacter baumannii and their implications. Sci Rep 2016; 6: 28291. 12 Lee JY, Park YK, Chung ES, Na IY, Ko KS. Evolved resistance to colistin and its loss due to genetic reversion in Pseudomonas aeruginosa. Sci Rep 2016; 6: 2